EIKN
Eikon Therapeutics, Inc. Common Stock NASDAQ$9.68
Mkt Cap $524.1M
52w Low $7.90
18.7% of range
52w High $17.40
50d MA $11.84
200d MA $12.24
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
—
ROE
—
P/FCF
—
RSI (14)
—
ATR (14)
—
Beta
0.00
50d MA
$11.84
200d MA
$12.24
Avg Volume
458.3K
About
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immun…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -3.56 | -27.00 | -658.4% | 9.68 | +0.9% | +9.3% | +4.1% | +2.3% | -2.5% | -9.3% | -5.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Wedbush | Maintains | Underperform → Underperform | — | $9.68 | $9.77 | +0.9% | +9.3% | +4.1% | +2.3% | -2.5% | -9.3% |
Recent Filings
8-K
Unknown — 8-K Filing
Eikon's Q4 2025 results and updates are critical for evaluating progress on clinical programs that could drive future revenue and justify its biotech valuation amid ongoing cash burn.
Mar 30
8-K
Eikon Therapeutics, Inc. -- 8-K Filing
Eikon Therapeutics filed an 8-K referencing its S-1 registration statement, indicating the company is progressing through SEC review for a potential initial public offering.
Feb 6
Data updated apr 25, 2026 6:45am
· Source: massive.com